{"nct_id":"NCT01621490","title":"PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma","status":"COMPLETED","status_verified_date":"2024-04","start_date":"2012-09-27","start_date_type":"ACTUAL","primary_completion_date":"2017-09-12","primary_completion_date_type":"ACTUAL","completion_date":"2018-10-25","completion_date_type":"ACTUAL","phases":["PHASE1"],"tickers":["BMY"]}